Many psychiatric disorders, despite their specific characteristics, share deficits in the
cognitive domain including executive functions, emotional control and memory. However …

It is now clearly established that complex interactions between genes and environment are
involved in multiple aspects of neuropsychiatric disorders, from determining an individual's …

Almost fifty years after its first introduction into clinical care, clozapine remains the only
evidence-based pharmacological option for treatment-resistant schizophrenia (TRS), which …

Antipsychotics represent the mainstay of schizophrenia pharmacological therapy, and their
role has been expanded in the last years to mood disorders treatment. Although introduced …

α2A-and α2C-adrenoceptors (ARs) are the primary α2-AR subtypes involved in central
nervous system (CNS) function. These receptors are implicated in the pathophysiology of …

Once considered only scaffolding proteins at glutamatergic postsynaptic density (PSD),
Homer1 proteins are increasingly emerging as multimodal adaptors that integrate different …

Dopamine-glutamate interplay dysfunctions have been suggested as pathophysiological
key determinants of major psychotic disorders, above all schizophrenia and mood disorders …

Emerging evidence from genomics, post-mortem, and preclinical studies point to a potential
dysregulation of molecular signaling at postsynaptic density (PSD) in schizophrenia …

Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide
and is conceptualized as a disorder of synaptic plasticity and brain connectivity …

Schizophrenia is a severe mental illness characterized by alterations in processes that
regulate both synaptic plasticity and functional connectivity between brain regions …